The International Society of Skeletal Dysplasia 2017 meeting report
2017-10-23Research
We report on the 2017 International Skeletal Dysplasia Society (ISDS) meeting. Previously unknown metabolic disturbances were discovered in achondroplasia and new results were presented on meclazine for achondroplasia.
Recruitment in clinical trials
2017-10-21Research
BioMarin shared a document with all associations updating everyone who is interested in their upcoming medications on their clinical trials. Read the whole document here.
Therachon heading to Phase 1 clinical trial
2017-06-25Research
Therachon is developing a drug for achondroplasia, which has now crossed an important threshold in drug development for rare diseases. It has obtained Orphan Drug designation by the American and European regulatory agencies (FDA and EMA, respectively), taking it a step closer to a possible market authorization.
BioMarin updates the Multicenter and Multinational Clinical Study 111-901
2017-06-03Research
This is an update on the observational study which collects information to establish a baseline for the other clinical trials by BioMarin. It is necessary to be enrolled in this one first for 6 months. Learn where to enroll here.
BioCentury published the article "Competing for growth"
2017-05-15Research
Part of an article originally posted by Biocentury about the potential new therapies for achondroplasia and how the competition between the pharmaceutical companies is being beneficial for the final product.
Phase 3 trial for achondroplasia - BioMarin Study 111-301
2017-05-12Research
Highlights of the Phase 3 clinical trial design for BMN-111, developed by BioMarin. Learn more about how it's going to be processed here.